Guttman-Yassky, E.; Blauvelt, A.; Eichenfield, L.; Paller, A.; Armstrong, A.; Drew, J.; Gopalan, R.; Simpson, E. Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. J of Skin 2019, 3, S41.